{
  "id": 20287460,
  "title": "Why is Aclaris Therapeutics Stock Trading Lower on Monday?",
  "url": "https://urgent.news/2026/11/16/why-is-aclaris-therapeutics-stock-trading-lower-on-monday",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T14:27:31.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/trading-ideas/movers/26/11/63290963/why-is-aclaris-therapeutics-stock-trading-lower-on-monday"
  },
  "original_language": "en",
  "account": "Aclaris Therapeutics stock prices declined on Monday as the company reported disappointing results from a Phase 2 trial of its experimental drug for atopic dermatitis. CEO Neal Walker assured investors that the biopharmaceutical firm would remain focused on advancing its core development programs, despite missing primary and secondary endpoints in the trial. Bosakitug, the drug in question, demonstrated some positive pharmacodynamic effects in patients, indicating strong engagement with its target. Aclaris also launched a new Phase 2b trial for a potential treatment of lichen planus, a chronic inflammatory skin condition. The company's stock dropped 13.52% in premarket trading following the report.",
  "summary": "Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study. Walker emphasized that Aclaris remains committed to advancing its oral kinase inhibitors and bispecific antibody programs toward major…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}